Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 27 clinical trials
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction (SPIRRIT)

: HFPEF patients in the Swedish Heart Failure Registry (2550 patients) and HFPEF patients in US (650 patients). HFPEF defined as symptoms/signs of HF, elevated NTproBNP (B-type Natriuretic Peptide; N

atrial fibrillation
b-type natriuretic peptide
n-terminal pro-bnp
pro-brain natriuretic peptide
  • 04 Oct, 2022
  • 67 locations
Reversible Pulmonary Artery Banding as Simplified Management of End-stage Dilated Left Ventriculopathy in Early Life

The purpose of this study is to: 1) Remodel and restore left ventricular geometry and function. 2) Avoid the need for mechanical circulatory support (MCS) and/or cardiac transplantation (CT). 3) Confirm the outcomes of a pilot study completed in Germany and reported in The Journal of Heart and Lung Transplantation …

  • 10 Apr, 2022
  • 1 location
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

Cardiomyopathy is a major complication of doxorubicin (DOX) chemotherapy, and 10-21% of breast cancer patients receiving DOX experience compromised cardiac function. Recent advancements have increased cancer survivorship but it remains clinically challenging to mitigate the cardiotoxic side effects. Although there are several strategies used to reduce the occurrence and severity …

  • 04 Oct, 2022
  • 1 location
Asian Diabetes Outcomes Prevention Trial (ADOPT)

The aim of this study is to identify patients with DM at high risk of CVD using elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (>125pg/mL), and (2) intensify therapy

primary prevention
heart failure
coronary revascularization
type 2 diabetes mellitus
  • 27 Feb, 2022
  • 1 location
Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke

outcome is recurrent stroke and the key secondary outcome is occurrence of major cardiovascular events by trial end. Additional biomarker outcomes are change in hs-CRP insulin resistance, B type

diabetes mellitus
glomerular filtration rate
insulin resistance
type 2 diabetes mellitus
  • 24 Mar, 2022
  • 1 location
Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

This is a double-blind, placebo-controlled and open-label, multicenter efficacy and long-term safety study of firibastat (QGC001) 1000 mg (2500 mg tablets) administered po, QD, for up to 48 weeks in patients with difficult-to-treat/treatment-resistant HTN. Subjects will continue to take their chronic antihypertensive therapies (at least 2 classes of antihypertensive therapies) …

antihypertensive drugs
resistant hypertension
blood pressure diastolic
  • 28 Sep, 2021
  • 2 locations
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, …

cell transplantation
  • 10 May, 2022
  • 98 locations
Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension

function with: World Health Organisation (WHO) class, Six-minute walk test, Quality of life (QoL), and Pre-specified biomarkers (N-terminal B-type natriuretic peptide (NT-ProBNP), Tissue growth factor-B B

endothelin receptor antagonist
walk tests
right heart catheterization
pulmonary arterial hypertension
  • 15 Feb, 2022
  • 1 location
Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)

-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) concentrations.

angiotensin ii receptor antagonists
ace inhibitor
b-type natriuretic peptide
heart failure
ejection fraction
  • 05 Jan, 2022
  • 1 location
CArvedilol SR in Patients With REduced Strain and Preserved Ejection Fraction Heart Failure (CARE-preserved HF): A Prospective Randomized, Double-Blinded, Multicenter Study

-terminal pro-B-type natriuretic peptide (NT-proBNP) > 400 pg/mL. The primary endpoint is the time-averaged proportional changes in NT-proBNP level from baseline through month 3. The secondary endpoints

  • 18 Oct, 2022
  • 2 locations